Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI – Get Rating), principal shareholder of Global Strategic Fund I. Venbio, sold 27,668 shares of Checkmate Pharmaceuticals in a trade dated Monday, April 25. The stock was sold at an average price of $10.39, for a total transaction of $287,470.52. Following the transaction, the insider now owns 3,060,542 shares of the company, valued at approximately $31,799,031.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders who own more than 10% of a company’s stock are required to disclose their sales and purchases to the SEC.

Shares of NASDAQ:CMPI traded up $0.01 during Tuesday’s trading, hitting $10.39. The stock had a trading volume of 271,706 shares, compared to an average volume of 101,046. The company has a fifty-day moving average price of $3.81 and a 200-day moving average price of 3.48 $. The stock has a market capitalization of $224.75 million, a P/E ratio of -3.65 and a beta of 0.61. Checkmate Pharmaceuticals, Inc. has a fifty-two week low of $2.00 and a fifty-two week high of $10.45.

Checkmate Pharmaceuticals (NASDAQ:CMPI – Get Rating) last released its results on Tuesday, March 29. The company reported ($0.62) earnings per share (EPS) for the quarter. Stock analysts expect Checkmate Pharmaceuticals, Inc. to post earnings per share of -3.14 for the current fiscal year.

An institutional investor recently bought a new position in shares of Checkmate Pharmaceuticals. Millennium Management LLC purchased a new stake in Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI – Get Rating) in the second quarter, according to its latest 13F filing with the Securities & Exchange Commission. The fund bought 40,422 shares of the company, valued at around $241,000. Millennium Management LLC owned 0.19% of Checkmate Pharmaceuticals when it last filed with the Securities & Exchange Commission. 75.12% of the shares are held by institutional investors.

A number of equity analysts have weighed in on CMPI shares recently. BTIG Research downgraded shares of Checkmate Pharmaceuticals from a “buy” rating to a “neutral” rating in a Wednesday, April 20 research report. Zacks Investment Research upgraded shares of Checkmate Pharmaceuticals from a “sell” rating to a “hold” rating in a Thursday, April 21 research report.

Checkmate Pharmaceuticals Company Profile (Get an evaluation)

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, is focused on developing and commercializing novel therapies for the treatment of cancer. It is developing CMP-001, which is in a phase II clinical trial in combination with pembrolizumab to treat patients with refractory PD-1 melanoma; combination with nivolumab to treat patients with naïve PD-1 neoadjuvant melanoma; and the treatment of patients with refractory PD-1 melanoma.

Read more

Insider buying and selling by quarter for Checkmate Pharmaceuticals (NASDAQ:CMPI)



Get news and reviews for Checkmate Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com’s free daily email newsletter.